BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

COVAX nearing $2B fund-raising goal for equitable vaccine distributionThe U.K., Canada, Germany, Italy and Sweden pledged $958 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC), which seeks to ensure equitable access to COVID-19...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jul 27, 2019
Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
BioCentury | Jul 15, 2019
Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
BioCentury | May 11, 2018

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature...
BioCentury | Mar 31, 2018

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
Items per page:
1 - 10 of 32